Servier IP

Servier is a leading international pharmaceutical group governed by a non-profit foundation, headquartered in Suresnes, France. The company operates across five main therapeutic areas: cardiovascular, immune-inflammatory, and neuropsychiatric diseases, cancer, and diabetes. In recent years, Servier has strategically pivoted to prioritize oncology, significantly expanding its portfolio through the acquisition of Shire's oncology business and Agios Pharmaceuticals' oncology branch. As a foundation-led organization, Servier reinvests over 20% of its commercial revenue into research and development to ensure long-term innovation and independence. The group maintains a global presence in over 150 countries and is the second-largest French pharmaceutical company.